Estradiol Tablets / Estradiol and Progesterone Tablets for Natural Menopause
China Estradiol Tablets / Estradiol and Progesterone Tablets for Natural Menopause, Find details about China Estradiol and Progesterone Tablets, Natural Menopause from Estradiol Tablets / Estradiol and Progesterone Tablets for Natural Menopause
Basic Info.
Model NO.
FC019
Model NO.
FC019
Product Desciption
Item Name: estradiol and progesterone tablets
Molecular formula
Item Description
Item nanme: estradiol and progesterone tablets
Item character:The goods is white
Indication:
Used for perimenopausal syndrome caused by natural or postoperative menopause
Item specifications: 2mg:10mg*28tab/box
Usage and dosage:One tablet was taken orally every 28 days as a course of treatment. On the first 14 days, one white tablet (containing 1 mg of estradiol) was taken orally, and on the next 14 days, one gray tablet (containing 1 mg of estradiol and 10 mg of didroxyprogesterone) was taken orally.
After 28 days of a course of treatment, the next course should be continued from the 29th day. Patients should take one tablet daily in the order indicated on the package. The drug should be taken continuously.
In the initial treatment and continuous treatment of menopause related symptoms, the minimum effective dose should be used in the shortest course of treatment.
Treatment of menopause related symptoms
Generally, the treatment should start with 1 / 10 of estradiol tablets / estradiol and didroxyprogesterone tablets. According to the clinical efficacy, the dose can be adjusted according to individual needs. If the discomfort related to estrogen deficiency is improved, the dosage can be increased and 2 / 10 of estradiol tablets / estradiol didroxyprogesterone tablets composite packaging can be used.
Or follow the doctor's advice.
Adverse reactions
The adverse reactions reported in clinical trials and after listing are as follows
breast cancer
A large number of epidemiological studies and a randomized placebo-controlled trial, women's Health Initiative (who), found that the overall risk of breast cancer increased with the increase in HRT treatment time in patients who are or have recently used HRT. For single estrogen replacement therapy, after a re analysis of 51 epidemiological studies (80% of the population using single estrogen replacement therapy) and an epidemiological study, namely, the millions Women Study (MWS), the results of similar users' relative risk of breast cancer (RR) were 1.35 (95% CI: 1.21-1.49) and 1.30 (95% CI: 1.21-1.40).
For HRT therapy combined with estrogen and progesterone, there have been several epidemiological studies that reported that the overall risk of breast cancer in users is higher than that of single estrogen users.
MWS reported that compared with those who had never used MRT, the risk of breast cancer (RR = 2.00, 95% CI: 1.88-2.12) was higher than that of single estrogen (RR = 1.30, 95% CI: 1.21-1.40) or tibolone (RR = 1.45, 95% CI: 1.25-1.68).
The WHO trial reported that all patients who used estrogen progesterone combined with HRT therapy (cee+mpa) had a risk of 1.24 (95% CI: 1.01-1.54) 5.6 years later.
The absolute risk of breast cancer calculated from MWS and who tests is as follows:
MWS based on the known incidence rate of breast cancer in developed countries:
About 32 of every 1000 women aged 50-64 who never used HRT were diagnosed with breast cancer
The number of new breast cancer cases is per 1000 patients of the same age who are or have recently used HRT therapy
Users of single estrogen replacement therapy
5 years of use in 0-3 cases (best estimate = 1.5)
10 years of use in 3-7 cases (best estimate = 5)
Users of estrogen and progesterone combined replacement therapy
5-7 cases (best estimate = 6) 5-year service life
18-20 cases (best estimate = 19) 10-year service life
After 5-6 years follow-up in the WHO trial, 8 cases of progressive breast cancer / 10000 women / year were added due to the combination of Estrogen Progesterone and HRT therapy (CEE + MPa).
According to the calculation results of test data, it can be concluded that:
Every 1000 women in the placebo group
About 16 cases will be diagnosed as progressive breast cancer within 5 years
The number of new cases in the Estrogen Progesterone combined with HRT (cee+mpa) group will be
5-year service life of 0-9 cases (best estimate = 4)
Women, regardless of age (45-65 years old) who started HRT therapy, had approximately the same number of new breast cancer cases.
Endometrial carcinoma
The risk of endometrial hyperplasia and endometrial cancer increased with the increase of the time of non antagonistic estrogen use in women with intact uterus. According to epidemiological data, the best risk estimate for endometrial cancer in women aged 50-65 years without HRT is about 5 cases / 1000. The risk of endometrial cancer in non antagonistic oestrogen users depends on the time and dose of estrogen, which is 2-12 times greater than that of the non HRT users. The increased risk can be greatly reduced by adding progesterone in single estrogen therapy.
Other adverse reactions related to estrogen / progesterone therapy
Estrogen depends on benign and malignant new organisms, such as endometrial cancer.
Venous thromboembolism, deep vein thrombosis and pulmonary embolism in legs or pelvis, is more common in hormone replacement users than in those who do not use HRT. For further information, see contraindications and precautions.
Taboo:
Known or suspected history of breast cancer
Known or suspected estrogen dependent malignancies (e.g. endometrial cancer)
Unexplained genital bleeding
Untreated endometrial hyperplasia
Previous idiopathic or existing venous thromboembolism (DVE, PE)
Active or recent arterial thromboembolic disease (e.g. angina pectoris, myocardial infarction)
In patients with acute liver disease or history of liver disease, the liver function index could not return to normal
Known to be allergic to the active component of this product or any excipient
Carbolinemia
(appropriate indications are not limited to postmenopausal women)
Known or suspected pregnancy
Matters needing attention:
HRT can only be started when menopause related symptoms have adverse effects on the quality of life. All cases should be carefully assessed for risks and benefits at least once a year, and HRT should be continued only when the benefits exceed the risks.
Physical examination / follow up
Before starting or re using HRT therapy, a comprehensive investigation of personal or family history should be conducted. At the same time, the contraindications and precautions of HRT therapy should be combined to guide physical examination (including pelvic and breast). During the treatment, it is suggested that regular physical examination should be carried out according to the individual situation of women. Women should report their breast changes to a doctor or nurse. Examination items, including mammography, should be adjusted according to the current recognized screening practice and individual needs.
Diseases requiring care
If you are suffering from any of the following diseases, or have occurred before, and / or worsened during pregnancy or previous hormone therapy, the patient should be closely monitored. It must be considered that these diseases may recur or worsen during the treatment of estradiol / estradiol and progesterone compound package
Leiomyoma (uterine fibroma) or endometriosis
History of thromboembolism or related risk factors (see below)
There are risk factors for estrogen dependent tumors, such as grade 1 inheritance of breast cancer
hypertension
Liver disease (e.g. liver adenoma)
Diabetes with or without angiopathy
Cholelithiasis
Migraine or (severe) headache
Systemic lupus erythematosus
History of endometrial hyperplasia (see below)
epilepsy
asthma
Otosclerosis
Reasons for immediate termination of treatment
If contraindications are found during treatment and the following conditions occur, the treatment should be stopped:
Jaundice or deterioration of liver function
The blood pressure increased significantly
New onset migraine
gestation
Endometrial hyperplasia
Long term single use of estrogen increases the risk of endometrial hyperplasia and endometrial cancer (see adverse reactions). For women who are not undergoing hysterectomy, adding at least 12 days of progesterone to each cycle can significantly reduce this risk.
In Chinese registered clinical trials, 1 case of simple endometrial hyperplasia was found in 2 / 10 group of estradiol / estradiol and didroxyprogesterone tablets, and 1 case of simple endometrial hyperplasia was found in control group (conjugated estrogen 0.625mg + medroxyprogesterone acetate 2mg).
Types of bleeding
Breakthrough bleeding and drip like bleeding may occur in the first few months of treatment. If breakthrough bleeding or drip like bleeding occurs after a period of treatment, or continues after treatment, the cause of bleeding should be investigated, including endometrial biopsy to exclude endometrial malignant transformation.
breast cancer
A randomized placebo-controlled trial, the women's Health Initiative (WHI), and multiple epidemiological studies. Including the million women study (MWS), it has been reported that women who have used estrogen, Estrogen Progesterone combination or tibolone as HRT therapy for many years have an increased risk of being diagnosed with breast cancer (see adverse reactions).
For all HRT treatments, the additional risk of breast cancer becomes apparent in the first few years of use and increases with the duration of treatment, but returns to baseline within a few years (up to 5 years) after discontinuation of treatment.
MWS found that combined estrogen (CEE) or estradiol (E2) increased the relative risk of breast cancer after sequential or continuous combination of any progesterone, and there was no difference between different routes of administration.
In the WHI study, the incidence of breast cancer was associated with the use of continuous combined estrogen and medroxyprogesterone acetate (CEE + MPa). Compared with the placebo group, these breast cancers had slightly larger volume and more frequent local lymph node metastasis.
HRT, especially the combination therapy of estrogen and progesterone, will increase the image density of mammography, which may not be conducive to the detection of breast cancer.
Venous thromboembolism
HRT therapy is associated with an increased relative risk of venous thromboembolism (VTE). A randomized controlled trial and several epidemiological studies have found that the risk of VTE of HRT users is 2-3 times higher than that of non users. It is estimated that the number of VTR cases of non HRT users in 5 years is about 3 / 1000 in women aged 50-59 and 8 / 1000 in women aged 60-69. It is estimated that the number of new VTE cases in healthy women in the five years of HRT therapy is about 2-6 (best estimate = 4) / 1000 in women aged 50-59, and 5-15 (best estimate = 9) / 1000 in women aged 60-69. VTE was more likely to occur in the first year of HRT than in the later years.
Generally recognized risk factors for VTE include personal or family history, severe obesity (body mass index] 30 kg / m2) and systemic lupus erythematosus (SLE). There is no consensus on the role of varicose veins in VTE.
Patients with a history of VTE or known thrombotic tendency have an increased risk of VTE. HRT therapy may increase the risk. If there is a personal or intensive family history of thromboembolism or recurrent spontaneous abortion, it should be investigated to exclude thrombotic tendency. HRT therapy should be considered contraindicated in these patients unless the risk factors for thrombotic tendency have been thoroughly assessed or anticoagulant therapy has been initiated. For women who have already started anticoagulant therapy, the benefits and risks of HRT should be carefully considered.
For a long time. Severe injury or major surgery may temporarily increase the risk of VTE. The prevention of VTE should be considered carefully for all patients after operation to prevent VTE. If possible, HRT should be stopped 4-6 weeks before operation. HRT should be resumed only when the female is fully autonomous.
If venous thromboembolism occurs after HRT, the drug should be stopped. Patients should be informed. If you are aware of symptoms that may be thromboembolism (such as painful edema in one leg, sudden chest pain, dyspnea), contact their doctor immediately.
Coronary heart disease (CAD)
Randomized controlled trials did not find cardiovascular benefits of continuous combined estrogen and MPA. 2 large-scale clinical trials (WHI and HERS, namely heart and estrogen / progestin replacement studies) showed that the incidence rate of cardiovascular disease may increase and no overall benefit during the first year of HRT therapy. Other HRT products have limited information on randomized controlled trials in terms of incidence rate or mortality rate. Therefore, it is not sure whether the above results can also be applied to other HRT products.
apoplexy
A large-scale randomized clinical trial (WHI trial) found. As a secondary outcome, healthy women had an increased risk of ischemic stroke during continuous combined estrogen and MPA treatment. It is estimated that the number of stroke cases in non HRT users within 5 years is about 3 cases / 1000 for women aged 50-59 and 11 cases / 1000 for women aged 60-69. The estimated use of conjugated estrogens and mpa5 in women for 5 years: 0-3 new cases (best estimate = 1 / 1000) in users aged 50-59, and 1-9 new cases (best estimate = 4 / 1000) in users aged 60-69. It is not clear whether the above results can also be applied to other HRT products.
oophoroma
Some epidemiological studies have found that long-term (at least 5-10 years) single use of estrogen HRT products in hysterectomy women increases the risk of ovarian cancer. It is not clear whether long-term use of HRT combined with ovarian cancer risk is different from single use of estrogen products.
Other diseases
* estrogen may cause fluid retention, so careful observation of patients with cardiac function or renal insufficiency should be made. The patients with end-stage renal insufficiency should be closely observed, because the circulating concentration of the active ingredient should be increased.
In estrogen replacement therapy or hormone replacement therapy, women with previous hypertriglyceridemia should be closely followed up, because it is rarely reported that estrogen treatment can significantly increase the plasma triglyceride level and lead to pancreatitis.
Estrogen increased the level of thyroxine binding globulin (TBG), and the total amount of circulating thyroxine was increased by protein bound iodine (PBI). T4 level (measured by column or radioimmunoassay) or T3 level (measured by radioimmunoassay) increased. The decrease of T3 resin uptake reflected the increase of TBG level. The concentrations of free T4 and free T3 remained unchanged. The serum concentration of other binding proteins may be increased. For example, adrenal cortisol binding globulin (CBG) and sex hormone binding globulin (SHBG) lead to increased levels of circulating corticosteroids and steroid sex hormones, respectively. The concentration of free or bioactive hormones remained unchanged. Other plasma proteins may be elevated (angiotensinogen / renin, alpha-i-insulin). Plasma ceruloplasmin (ceruloplasmin).
At present, there is no final conclusion on improving cognitive function. Evidence from the WHI trial suggests that the risk of dementia is likely to increase in women who start to use the combination of CEE and MPA after the age of 65. It is not clear whether this result also applies to younger postmenopausal women or other HRT products.
(appropriate indications are not limited to postmenopausal women)
This Estrogen Progesterone combination therapy is not a contraceptive. It is suggested that non hormonal contraception should be used for menopausal patients.
Medication for pregnant and lactating women:
This product should not be used during pregnancy. If pregnancy occurs during the treatment, the drug should be stopped immediately.
A large number of cases of pregnancy exposure showed that didroxyprogesterone had no harmful effect on the fetus.
So far, most epidemiological studies have shown that there is no teratogenic effect or fetal toxicity when the fetus is inadvertently exposed to combined estrogen and progesterone.
This product should not be used during lactation.
FAQ
1.who are we?
We are based in Fujian, China, start from 2000,sell to North America(40.00%),Southeast Asia(25.00%),Western Europe(25.00%),Africa(10.00%).There are total about 50 people in our office.
2. how can we guarantee quality?
Always a pre-production sample before mass production;
Always final Inspection before shipment;
3.what can you buy from us?
Pharmaceutical production lines,Intermediates,APIs,Finished Drug Preparations & Vaccines.
4. why should you buy from us not from other suppliers?
We have our own manufacture factories and one professional sales team working for the clients all over the world.
5. what services can we provide?
Accepted Delivery Terms: FOB,CIF,EXW,DDP,Express Delivery;
Accepted Payment Currency:USD,EUR,CAD,AUD,GBP,CNY;
Accepted Payment Type: T/T,L/C,PayPal,Western Union;
Language Spoken:English,Chinese,Japanese
Our Ddvantage:
1. Quick delivery
2. Online payment
3. Quality assurance
4. Welcome big order
5. After-sales service 24 hours
6. Competitive advantage products
7. Our value information is "Quality is our culture"
8. Work with us to provide you with secure funds, your business is securely protected, our advantages
Our Service
a) Free amples can be provided.
b) Guide customers through professional technology and teach them how to use our products after sale
c) Determine the lowest price of high-quality products
1. Skilled experience: Our company is a leading manufacturer of professional production in China pharmaceutical field for many years.
2. The highest quality: to ensure high quality, once any problems are found, the package will be re-shipped for you.
3. Safe transportation: by air express (FedEx, UPS, DHL, EMS). It is recommended that you choose the most professional freight forwarder.
4. Fast delivery: We have stock, so once payment is received, we can deliver quickly.
5. Quality service: We will provide you with enthusiastic after-sales service. If you have any questions, we will reply to youwithin 24 hours.
6. Competitive price: discounts will be obtained when making large orders.
Our Manufacture Factory
Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd is a comprehensive enterprise which integrates R & D, production and construction of pharmaceutical production equipments, development and transfer of biotechnology, and cooperative production and sales of drugs and vaccines. The self-developed pharmaceutical production equipment branded FUL has been put into operation in many well-known pharmaceutical enterprises such as SINOPHARM, CSPC and also cooperates with many well-known pharmaceutical enterprises in production and sales, including pharmaceutical intermediates, APIs and finished drug preparations.
Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd business radiates to all levels, including direct supply cooperation with government departments and industry representatives, as well as establishing supply cooperation relationship with retail industry. We supply high quality, safe and effective medicines and medical equipment to governments, hospitals, clinics and licensed pharmacies in different countries with timely and effective services at reasonable prices.
At present Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd has the SINOPHARM authorization to sell its intermediates and APIs,and has the authorizations of CSPC & HUABEI PHARM sell its finished drug preparations;then FUL is the only manufacture in China which can supply the complete service from pharmaceutical produciton lines,intermediates and APIs to finished drug preparations and vaccines.Then we are seeking the professional pharmaceutical enterprices to work together for further cooperations.
Factory View
Our Products
Our Business
Molecular formula
Item Description
Item nanme: estradiol and progesterone tablets
Item character:The goods is white
Indication:
Used for perimenopausal syndrome caused by natural or postoperative menopause
Item specifications: 2mg:10mg*28tab/box
Usage and dosage:One tablet was taken orally every 28 days as a course of treatment. On the first 14 days, one white tablet (containing 1 mg of estradiol) was taken orally, and on the next 14 days, one gray tablet (containing 1 mg of estradiol and 10 mg of didroxyprogesterone) was taken orally.
After 28 days of a course of treatment, the next course should be continued from the 29th day. Patients should take one tablet daily in the order indicated on the package. The drug should be taken continuously.
In the initial treatment and continuous treatment of menopause related symptoms, the minimum effective dose should be used in the shortest course of treatment.
Treatment of menopause related symptoms
Generally, the treatment should start with 1 / 10 of estradiol tablets / estradiol and didroxyprogesterone tablets. According to the clinical efficacy, the dose can be adjusted according to individual needs. If the discomfort related to estrogen deficiency is improved, the dosage can be increased and 2 / 10 of estradiol tablets / estradiol didroxyprogesterone tablets composite packaging can be used.
Or follow the doctor's advice.
Adverse reactions
The adverse reactions reported in clinical trials and after listing are as follows
breast cancer
A large number of epidemiological studies and a randomized placebo-controlled trial, women's Health Initiative (who), found that the overall risk of breast cancer increased with the increase in HRT treatment time in patients who are or have recently used HRT. For single estrogen replacement therapy, after a re analysis of 51 epidemiological studies (80% of the population using single estrogen replacement therapy) and an epidemiological study, namely, the millions Women Study (MWS), the results of similar users' relative risk of breast cancer (RR) were 1.35 (95% CI: 1.21-1.49) and 1.30 (95% CI: 1.21-1.40).
For HRT therapy combined with estrogen and progesterone, there have been several epidemiological studies that reported that the overall risk of breast cancer in users is higher than that of single estrogen users.
MWS reported that compared with those who had never used MRT, the risk of breast cancer (RR = 2.00, 95% CI: 1.88-2.12) was higher than that of single estrogen (RR = 1.30, 95% CI: 1.21-1.40) or tibolone (RR = 1.45, 95% CI: 1.25-1.68).
The WHO trial reported that all patients who used estrogen progesterone combined with HRT therapy (cee+mpa) had a risk of 1.24 (95% CI: 1.01-1.54) 5.6 years later.
The absolute risk of breast cancer calculated from MWS and who tests is as follows:
MWS based on the known incidence rate of breast cancer in developed countries:
About 32 of every 1000 women aged 50-64 who never used HRT were diagnosed with breast cancer
The number of new breast cancer cases is per 1000 patients of the same age who are or have recently used HRT therapy
Users of single estrogen replacement therapy
5 years of use in 0-3 cases (best estimate = 1.5)
10 years of use in 3-7 cases (best estimate = 5)
Users of estrogen and progesterone combined replacement therapy
5-7 cases (best estimate = 6) 5-year service life
18-20 cases (best estimate = 19) 10-year service life
After 5-6 years follow-up in the WHO trial, 8 cases of progressive breast cancer / 10000 women / year were added due to the combination of Estrogen Progesterone and HRT therapy (CEE + MPa).
According to the calculation results of test data, it can be concluded that:
Every 1000 women in the placebo group
About 16 cases will be diagnosed as progressive breast cancer within 5 years
The number of new cases in the Estrogen Progesterone combined with HRT (cee+mpa) group will be
5-year service life of 0-9 cases (best estimate = 4)
Women, regardless of age (45-65 years old) who started HRT therapy, had approximately the same number of new breast cancer cases.
Endometrial carcinoma
The risk of endometrial hyperplasia and endometrial cancer increased with the increase of the time of non antagonistic estrogen use in women with intact uterus. According to epidemiological data, the best risk estimate for endometrial cancer in women aged 50-65 years without HRT is about 5 cases / 1000. The risk of endometrial cancer in non antagonistic oestrogen users depends on the time and dose of estrogen, which is 2-12 times greater than that of the non HRT users. The increased risk can be greatly reduced by adding progesterone in single estrogen therapy.
Other adverse reactions related to estrogen / progesterone therapy
Estrogen depends on benign and malignant new organisms, such as endometrial cancer.
Venous thromboembolism, deep vein thrombosis and pulmonary embolism in legs or pelvis, is more common in hormone replacement users than in those who do not use HRT. For further information, see contraindications and precautions.
Taboo:
Known or suspected history of breast cancer
Known or suspected estrogen dependent malignancies (e.g. endometrial cancer)
Unexplained genital bleeding
Untreated endometrial hyperplasia
Previous idiopathic or existing venous thromboembolism (DVE, PE)
Active or recent arterial thromboembolic disease (e.g. angina pectoris, myocardial infarction)
In patients with acute liver disease or history of liver disease, the liver function index could not return to normal
Known to be allergic to the active component of this product or any excipient
Carbolinemia
(appropriate indications are not limited to postmenopausal women)
Known or suspected pregnancy
Matters needing attention:
HRT can only be started when menopause related symptoms have adverse effects on the quality of life. All cases should be carefully assessed for risks and benefits at least once a year, and HRT should be continued only when the benefits exceed the risks.
Physical examination / follow up
Before starting or re using HRT therapy, a comprehensive investigation of personal or family history should be conducted. At the same time, the contraindications and precautions of HRT therapy should be combined to guide physical examination (including pelvic and breast). During the treatment, it is suggested that regular physical examination should be carried out according to the individual situation of women. Women should report their breast changes to a doctor or nurse. Examination items, including mammography, should be adjusted according to the current recognized screening practice and individual needs.
Diseases requiring care
If you are suffering from any of the following diseases, or have occurred before, and / or worsened during pregnancy or previous hormone therapy, the patient should be closely monitored. It must be considered that these diseases may recur or worsen during the treatment of estradiol / estradiol and progesterone compound package
Leiomyoma (uterine fibroma) or endometriosis
History of thromboembolism or related risk factors (see below)
There are risk factors for estrogen dependent tumors, such as grade 1 inheritance of breast cancer
hypertension
Liver disease (e.g. liver adenoma)
Diabetes with or without angiopathy
Cholelithiasis
Migraine or (severe) headache
Systemic lupus erythematosus
History of endometrial hyperplasia (see below)
epilepsy
asthma
Otosclerosis
Reasons for immediate termination of treatment
If contraindications are found during treatment and the following conditions occur, the treatment should be stopped:
Jaundice or deterioration of liver function
The blood pressure increased significantly
New onset migraine
gestation
Endometrial hyperplasia
Long term single use of estrogen increases the risk of endometrial hyperplasia and endometrial cancer (see adverse reactions). For women who are not undergoing hysterectomy, adding at least 12 days of progesterone to each cycle can significantly reduce this risk.
In Chinese registered clinical trials, 1 case of simple endometrial hyperplasia was found in 2 / 10 group of estradiol / estradiol and didroxyprogesterone tablets, and 1 case of simple endometrial hyperplasia was found in control group (conjugated estrogen 0.625mg + medroxyprogesterone acetate 2mg).
Types of bleeding
Breakthrough bleeding and drip like bleeding may occur in the first few months of treatment. If breakthrough bleeding or drip like bleeding occurs after a period of treatment, or continues after treatment, the cause of bleeding should be investigated, including endometrial biopsy to exclude endometrial malignant transformation.
breast cancer
A randomized placebo-controlled trial, the women's Health Initiative (WHI), and multiple epidemiological studies. Including the million women study (MWS), it has been reported that women who have used estrogen, Estrogen Progesterone combination or tibolone as HRT therapy for many years have an increased risk of being diagnosed with breast cancer (see adverse reactions).
For all HRT treatments, the additional risk of breast cancer becomes apparent in the first few years of use and increases with the duration of treatment, but returns to baseline within a few years (up to 5 years) after discontinuation of treatment.
MWS found that combined estrogen (CEE) or estradiol (E2) increased the relative risk of breast cancer after sequential or continuous combination of any progesterone, and there was no difference between different routes of administration.
In the WHI study, the incidence of breast cancer was associated with the use of continuous combined estrogen and medroxyprogesterone acetate (CEE + MPa). Compared with the placebo group, these breast cancers had slightly larger volume and more frequent local lymph node metastasis.
HRT, especially the combination therapy of estrogen and progesterone, will increase the image density of mammography, which may not be conducive to the detection of breast cancer.
Venous thromboembolism
HRT therapy is associated with an increased relative risk of venous thromboembolism (VTE). A randomized controlled trial and several epidemiological studies have found that the risk of VTE of HRT users is 2-3 times higher than that of non users. It is estimated that the number of VTR cases of non HRT users in 5 years is about 3 / 1000 in women aged 50-59 and 8 / 1000 in women aged 60-69. It is estimated that the number of new VTE cases in healthy women in the five years of HRT therapy is about 2-6 (best estimate = 4) / 1000 in women aged 50-59, and 5-15 (best estimate = 9) / 1000 in women aged 60-69. VTE was more likely to occur in the first year of HRT than in the later years.
Generally recognized risk factors for VTE include personal or family history, severe obesity (body mass index] 30 kg / m2) and systemic lupus erythematosus (SLE). There is no consensus on the role of varicose veins in VTE.
Patients with a history of VTE or known thrombotic tendency have an increased risk of VTE. HRT therapy may increase the risk. If there is a personal or intensive family history of thromboembolism or recurrent spontaneous abortion, it should be investigated to exclude thrombotic tendency. HRT therapy should be considered contraindicated in these patients unless the risk factors for thrombotic tendency have been thoroughly assessed or anticoagulant therapy has been initiated. For women who have already started anticoagulant therapy, the benefits and risks of HRT should be carefully considered.
For a long time. Severe injury or major surgery may temporarily increase the risk of VTE. The prevention of VTE should be considered carefully for all patients after operation to prevent VTE. If possible, HRT should be stopped 4-6 weeks before operation. HRT should be resumed only when the female is fully autonomous.
If venous thromboembolism occurs after HRT, the drug should be stopped. Patients should be informed. If you are aware of symptoms that may be thromboembolism (such as painful edema in one leg, sudden chest pain, dyspnea), contact their doctor immediately.
Coronary heart disease (CAD)
Randomized controlled trials did not find cardiovascular benefits of continuous combined estrogen and MPA. 2 large-scale clinical trials (WHI and HERS, namely heart and estrogen / progestin replacement studies) showed that the incidence rate of cardiovascular disease may increase and no overall benefit during the first year of HRT therapy. Other HRT products have limited information on randomized controlled trials in terms of incidence rate or mortality rate. Therefore, it is not sure whether the above results can also be applied to other HRT products.
apoplexy
A large-scale randomized clinical trial (WHI trial) found. As a secondary outcome, healthy women had an increased risk of ischemic stroke during continuous combined estrogen and MPA treatment. It is estimated that the number of stroke cases in non HRT users within 5 years is about 3 cases / 1000 for women aged 50-59 and 11 cases / 1000 for women aged 60-69. The estimated use of conjugated estrogens and mpa5 in women for 5 years: 0-3 new cases (best estimate = 1 / 1000) in users aged 50-59, and 1-9 new cases (best estimate = 4 / 1000) in users aged 60-69. It is not clear whether the above results can also be applied to other HRT products.
oophoroma
Some epidemiological studies have found that long-term (at least 5-10 years) single use of estrogen HRT products in hysterectomy women increases the risk of ovarian cancer. It is not clear whether long-term use of HRT combined with ovarian cancer risk is different from single use of estrogen products.
Other diseases
* estrogen may cause fluid retention, so careful observation of patients with cardiac function or renal insufficiency should be made. The patients with end-stage renal insufficiency should be closely observed, because the circulating concentration of the active ingredient should be increased.
In estrogen replacement therapy or hormone replacement therapy, women with previous hypertriglyceridemia should be closely followed up, because it is rarely reported that estrogen treatment can significantly increase the plasma triglyceride level and lead to pancreatitis.
Estrogen increased the level of thyroxine binding globulin (TBG), and the total amount of circulating thyroxine was increased by protein bound iodine (PBI). T4 level (measured by column or radioimmunoassay) or T3 level (measured by radioimmunoassay) increased. The decrease of T3 resin uptake reflected the increase of TBG level. The concentrations of free T4 and free T3 remained unchanged. The serum concentration of other binding proteins may be increased. For example, adrenal cortisol binding globulin (CBG) and sex hormone binding globulin (SHBG) lead to increased levels of circulating corticosteroids and steroid sex hormones, respectively. The concentration of free or bioactive hormones remained unchanged. Other plasma proteins may be elevated (angiotensinogen / renin, alpha-i-insulin). Plasma ceruloplasmin (ceruloplasmin).
At present, there is no final conclusion on improving cognitive function. Evidence from the WHI trial suggests that the risk of dementia is likely to increase in women who start to use the combination of CEE and MPA after the age of 65. It is not clear whether this result also applies to younger postmenopausal women or other HRT products.
(appropriate indications are not limited to postmenopausal women)
This Estrogen Progesterone combination therapy is not a contraceptive. It is suggested that non hormonal contraception should be used for menopausal patients.
Medication for pregnant and lactating women:
This product should not be used during pregnancy. If pregnancy occurs during the treatment, the drug should be stopped immediately.
A large number of cases of pregnancy exposure showed that didroxyprogesterone had no harmful effect on the fetus.
So far, most epidemiological studies have shown that there is no teratogenic effect or fetal toxicity when the fetus is inadvertently exposed to combined estrogen and progesterone.
This product should not be used during lactation.
FAQ
1.who are we?
We are based in Fujian, China, start from 2000,sell to North America(40.00%),Southeast Asia(25.00%),Western Europe(25.00%),Africa(10.00%).There are total about 50 people in our office.
2. how can we guarantee quality?
Always a pre-production sample before mass production;
Always final Inspection before shipment;
3.what can you buy from us?
Pharmaceutical production lines,Intermediates,APIs,Finished Drug Preparations & Vaccines.
4. why should you buy from us not from other suppliers?
We have our own manufacture factories and one professional sales team working for the clients all over the world.
5. what services can we provide?
Accepted Delivery Terms: FOB,CIF,EXW,DDP,Express Delivery;
Accepted Payment Currency:USD,EUR,CAD,AUD,GBP,CNY;
Accepted Payment Type: T/T,L/C,PayPal,Western Union;
Language Spoken:English,Chinese,Japanese
Our Ddvantage:
1. Quick delivery
2. Online payment
3. Quality assurance
4. Welcome big order
5. After-sales service 24 hours
6. Competitive advantage products
7. Our value information is "Quality is our culture"
8. Work with us to provide you with secure funds, your business is securely protected, our advantages
Our Service
a) Free amples can be provided.
b) Guide customers through professional technology and teach them how to use our products after sale
c) Determine the lowest price of high-quality products
1. Skilled experience: Our company is a leading manufacturer of professional production in China pharmaceutical field for many years.
2. The highest quality: to ensure high quality, once any problems are found, the package will be re-shipped for you.
3. Safe transportation: by air express (FedEx, UPS, DHL, EMS). It is recommended that you choose the most professional freight forwarder.
4. Fast delivery: We have stock, so once payment is received, we can deliver quickly.
5. Quality service: We will provide you with enthusiastic after-sales service. If you have any questions, we will reply to youwithin 24 hours.
6. Competitive price: discounts will be obtained when making large orders.
Our Manufacture Factory
Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd is a comprehensive enterprise which integrates R & D, production and construction of pharmaceutical production equipments, development and transfer of biotechnology, and cooperative production and sales of drugs and vaccines. The self-developed pharmaceutical production equipment branded FUL has been put into operation in many well-known pharmaceutical enterprises such as SINOPHARM, CSPC and also cooperates with many well-known pharmaceutical enterprises in production and sales, including pharmaceutical intermediates, APIs and finished drug preparations.
Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd business radiates to all levels, including direct supply cooperation with government departments and industry representatives, as well as establishing supply cooperation relationship with retail industry. We supply high quality, safe and effective medicines and medical equipment to governments, hospitals, clinics and licensed pharmacies in different countries with timely and effective services at reasonable prices.
At present Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd has the SINOPHARM authorization to sell its intermediates and APIs,and has the authorizations of CSPC & HUABEI PHARM sell its finished drug preparations;then FUL is the only manufacture in China which can supply the complete service from pharmaceutical produciton lines,intermediates and APIs to finished drug preparations and vaccines.Then we are seeking the professional pharmaceutical enterprices to work together for further cooperations.
Factory View
Our Products
Our Business
You Might Also Like
Triac 0-10V Dali Dimmable Recessed LED Downlight/ COB LED Ce......
GMP Factory Supply Food Grade Phycocyanin Spirulina Extract
Table Tennis Racket with Rubber + Bag Ping Pong Bat
3mh Cool Giant Fat Inflatable Cat Cartoon for Advertising
Mslfp14 17*17 Wired Box Size X-ray Digital Flat Panel Detect......
Portable Glass Shape Edge Polishing Machine
A4 A3 Paper Wrapping Machine
Stainless Steel Angle Tube Strainer
Sinchold 9220/20/45 Forged Steel Welded Crane Rail Clips
Warehouse Tent Made by Superb Tent
Thyristor Rectified CO2 MIG Mag Arc Welding Machine